SciBase Holding AB (STO: SCIB) reported on Wednesday that it has launched a pilot program at a prominent private research university in southeast Florida to integrate its Nevisense platform into clinical workflows for skin cancer detection.

The pilot aims to evaluate Nevisense's effectiveness in early skin cancer diagnosis at the point-of-care across dermatological settings. The university is internationally recognised for its leadership in dermatological research and treatment, and maintains a high research classification, with specialised centres focusing on data-driven solutions and European policy research.

Nevisense, developed by SciBase, is an AI-powered platform that combines advanced electrical impedance spectroscopy (EIS) technology to improve diagnostic accuracy. The solution supports early intervention, aiming to reduce patient suffering and long-term healthcare costs.

SciBase, headquartered in Sweden and founded on research from the Karolinska Institute, is a global medtech company focused on prevention and early detection in dermatology.